Filing Details

Accession Number:
0001140361-15-037186
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-10-08 16:14:40
Reporting Period:
2015-10-06
Filing Date:
2015-10-08
Accepted Time:
2015-10-08 16:14:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1472091 Edge Therapeutics Inc. EDGE Pharmaceutical Preparations (2834) 264231384
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1492256 J. Robert Spiegel 200 Connell Drive, Suite 1600
Berkeley Heights NJ 07922
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-10-06 23,579 $0.00 23,579 No 4 C Direct
Common Stock Acquisiton 2015-10-06 10,533 $0.00 34,112 No 4 C Direct
Common Stock Acquisiton 2015-10-06 3,000 $11.00 37,112 No 4 P Direct
Common Stock Acquisiton 2015-10-06 1,549 $7.91 38,661 No 4 J Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
No 4 J Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C-1 Convertible Preferred Stock Disposition 2015-10-06 32,258 $0.00 23,579 $0.00
Common Stock Series C-2 Convertible Preferred Stock Disposition 2015-10-06 14,409 $0.00 10,533 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The convertible preferred stock converted into the Issuer's common stock at a conversion ratio, as adjusted to give effect to the Issuer's 1-for-1.3681 reverse stock split effected on September 21, 2015, of one share of common stock for every 1.3681 shares of preferred stock immediately prior to the closing of the Issuer's initial public offering of common stock, and had no expiration date.
  2. The Reporting Person received a total of 1,549 shares of the Issuer's common stock, which represented a payment-in-kind dividend on 46,667 shares of the Issuer's convertible preferred stock owned at the time of the dividend payment date.